Non-traumatic Subarachnoid Haemorrhage
Conditions
Brief summary
A subarachnoid hemorrhage occurs in about 10 out of 100,000 people each year. This bleeding leads to irritation and constriction of blood vessels in the brain (vasospasm) in two out of three people affected within four to 21 days and thus to reduced blood flow. This can lead to a stroke and serious damage. In order to be able to diagnose and treat a constriction of the blood vessels at an early stage, there are various examination methods which, however, have various disadvantages such as radiation exposure of the patient, low sensitivity or high effort. Therefore, the prediction and timely therapy of vascular constrictions is currently only successful in a few cases before the reduced blood flow has already led to irreversible damage. The aim of this study is to investigate whether the so-called retinal vascular analysis can be used in addition to previous standard examinations for the early detection of diseases of the cerebral blood circulation. This method has few side effects and has been successfully used for 50 years to examine the blood circulation in the eye.
Interventions
DIAGNOSTIC_TESTretinal vascular analysis
Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
Sponsors
RWTH Aachen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female or male patient, age ≥ 18 years * Inpatient stay in the clinic * Written informed consent for participation in the study prior to beginning of treatment * Written consent for further evaluation of the images and for the scientific publication of the study results * Non-traumatic subarachnoid haemorrhage confirmed by computer tomography or magnetic resonance tomography or cerebrospinal fluid puncture (collection of nerve water from the lower part of the lumbar spine
Exclusion criteria
* Female or male patient \< 18 years * Pregnancy, Lactation * Lack of written consent to participate in the study and to further evaluate the image material collected * Known allergy to MS eye drops (active substance: phenylephrine/tropicamide * Narrow chamber angle, narrow angle glaucoma, Terson syndrome (if it makes retinal vascular imaging impossible * Persons in a dependency or employment relationship with the investigator * Persons who are accommodated in a facility by judicial or administrative order * Receipt and intake of a study drug within the last 30 days * Supine position in bed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Progression of Delayed cortical ischemia | 21 days | Delayed cortical ischemia as ischemia in cranial computer tomography or cranial magnetic resonance tomography that occurred later than 24 hours after admission to hospital |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic deficiency supply | 21 days | Measured as change in lactate-pyruvate ratio in microdialysis |
| Relative underperfusion | 21 days | Measured by Perfusion-Computer-Tomography |
| Occurrence of delayed ischemic neurological deficit (DIND) | 21 days | — |
| Angiographic vasospasm | 7 days | Occurence of an angiographic vasospasm measured by: * Digital subtraction angiography at day 7 +/- 2 days or * transcranial doppler sonography: flow increase \>150 cm/s absolute or increase \>50 cm/s within 24 h |
| Objective degree of recovery | 3 Month | Measured by Glasgow-Outcome-Scale; Scale by which patients who have experienced brain damage can be divided into 5 groups that allow to describe the degree of recovery in a standardized and objective manner (1: death; 2: vegetative condition, the patient is unresponsive. The higher cognitive functions are extinguished; 3: severe disability, the patient is conscious, but cannot cope with normal everyday activities without help; 4: moderate disability, the patient can live largely independently, but is not able to pursue a normal working life; 5: light to no handicap, the neurological, physical, and psychological deficits are so low that the patient can participate normally in social and economic activities) |
Countries
Germany
Contacts
Primary ContactGerrit A Schubert, Prof. Dr.
Outcome results
None listed